Plain-English translation of NCT04009265 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
After surgery to remove esophageal cancer, doctors don't yet know the best way to prevent the cancer from coming back. This trial randomly assigns patients to one of three groups: some receive chemotherapy (using drugs like Docetaxel and cisplatin), some receive chemotherapy combined with radiation therapy, and some receive surgery alone with no additional treatment. The goal is to find out which approach helps patients live longer and stay cancer-free.
Esophageal cancer that has spread to nearby lymph nodes is serious and often comes back after surgery. Doctors want to know whether adding chemotherapy or radiation after surgery can improve survival and reduce the chance of the cancer returning, compared to surgery by itself.
If you join this trial, you will be randomly assigned to one of three groups after your surgery heals. You might receive two cycles of chemotherapy over several weeks, or chemotherapy combined with radiation therapy over about five weeks, or no additional treatment at all. The study team will monitor your health regularly with blood tests and scans to track how you're doing and watch for any side effects. Your participation will help doctors understand the best way to treat esophageal cancer.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Fujian Medical University Union Hospital
Enrollment target
~145 participants
Started
August 2019
Primary completion
September 2024
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in October 2026.